13F Portfolios

Duquesne Family Office LLC — NEWAMSTERDAM PHARMA COMPANY NAMS: Quarterly 13F Position History

Duquesne Family Office LLC has reported NEWAMSTERDAM PHARMA COMPANY (NAMS) on 7 13F-HR filings in Pactolio's tracked window, first appearing in Q3 2024. As of Q1 2026, the position is sized at 3,070,146 shares ($98.3M market value, 3.35% of the equity book).

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 7 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 3,070,146 0 $98.3M 3.35% $32.01
Q4 2025 3,070,146 +1,146,446 +59.6% $107.7M 2.55% $35.08
Q3 2025 1,923,700 +1,091,525 +131.2% $54.7M 1.39% $28.44
Q2 2025 832,175 +31,815 +4.0% $15.1M 0.39% $18.11
Q1 2025 800,360 +512,825 +178.4% $16.4M 0.55% $20.47
Q4 2024 287,535 0 $7.4M 0.21% $25.70
Q3 2024 287,535 $4.8M 0.17% $16.60

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Duquesne Family Office LLC first disclose a NAMS position in 13F-HR filings?

Duquesne Family Office LLC first reported NEWAMSTERDAM PHARMA COMPANY (NAMS) on its 13F-HR filing for the period ending 2024-09-30 (Q3 2024). The position has appeared on 7 reported quarters within Pactolio's tracked window.

What was Duquesne Family Office LLC's most recent quarter-over-quarter share-count change in NAMS?

Duquesne Family Office LLC held the same 3,070,146 shares of NAMS between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.

Does the implied price-per-share represent Duquesne Family Office LLC's cost basis in NAMS?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.